ALS Clinical Trial
Official title:
Digital Tools for Assessment of Motor Functions and Falls in ALS
This is a 48-week single arm study that incorporates digital tools for assessing motor function as part of an ALS telemonitoring program. During the study, neck- and wrist-worn "activity sensors" (PAMSys, BioSensics, Newton, MA) that will be worn by subjects while performing tasks of daily living. Subjects will also complete a motor, speech, and handwriting assessment during site visits. Subjects will complete a digital home assessments of speech, handwriting, and pattern tracing tasks throughout the study, and report any falls which occur on the study tablet. The investigators will explore whether functional changes are sensitive to self-reported changes on the ALS Functional Rating Scale - Revised (ALFRS-R) over the length of the study.
Many of the recognized intrinsic factors for falls are commonly seen in ALS, including advanced age, muscle weakness, gait and balance problems, and previous falls. The American Academy of Neurology ALS Quality Standards Committee recommends querying patients for falls occurring in the past 12 months, indicating that prevention of falls is an important part of disease management. Despite this, the determinants and prevention of falls in this population is critically understudied. Among frail older adults, fallers (those who reported at least 1 fall in the last 6-months) spent more than twice as much time walking as non-fallers (those who reported no falls in the last 6-months). For these individuals, the best predictors of falling are measures related to activity exposure, such as time spent walking, average walking bout duration, or steps per day. Activity metrics of cadence variability, peak vertical acceleration variability, average duration of episodes of walking, frontal acceleration variability, average peak vertical acceleration, and average cadence have been shown to be associated with fall risk. During walking, individuals with ALS have increased and highly variable gait cycle time (time to complete a full walking cycle), along with reduced stride length with increased variability in stride length compared to healthy controls. The ability to observe changes in gait and posture has rapidly advanced around a revolution in mobile health technology. Inertial measurement units (IMUs), a standard inclusion of nearly all new smartphone/smartwatch devices, are small electronic chips that detect different aspects of inertial change, notably linear acceleration, angular velocity, and position relative to the magnetic field of the earth. Unlike their expansive use in movement disorders like Parkinson's disease, IMU-based gait assessment has been largely absent in ALS, despite the rapid changes to gait that may occur. The standard model for assessing and acting upon functional motor changes, including those impacting gait and falls, occurs roughly once every three months when patients are seen in the outpatient setting. Furthermore, self-reporting of falls has been shown to suffer from recall bias, resulting in low sensitivity and underreporting of fall events. In summary, patients with a rapidly progressing neurodegenerative disease, who in the standard care setting receive physical assessment motor function every three months, might stand to benefit from a home-based, objective biomarker for functional motor changes. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Completed |
NCT02405182 -
MRI Biomarkers in ALS
|
||
Completed |
NCT00696332 -
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT03865420 -
Amyotrophic Lateral Sclerosis (ALS) Families Project
|
||
Terminated |
NCT04054141 -
rTMS in Treatment of Spasticity
|
N/A | |
Recruiting |
NCT03272503 -
A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Completed |
NCT05568615 -
Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
|
Phase 3 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Active, not recruiting |
NCT04259255 -
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
|
||
Recruiting |
NCT02495571 -
Assessment of Voluntary and Reflex Cough in Patients With ALS
|
N/A | |
Completed |
NCT02525471 -
A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)
|
Phase 1 | |
Recruiting |
NCT05031351 -
NF-κB Inhibition in Amyotrophic Lateral Sclerosis
|
Phase 2 | |
Active, not recruiting |
NCT05581771 -
Factors Associated With Success of NIPPV in ALS Patients
|
||
Active, not recruiting |
NCT03268603 -
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Completed |
NCT06005506 -
National Multicenter Interventional Study Aimed at Evaluating the Effect on the Intestinal Microbiota in Chronically Frail Patients Who Share Alterations in Intestinal Function.
|
N/A | |
Recruiting |
NCT04138095 -
Virtual Reality as an Adjunct to Management of Pain and Anxiety in Palliative Care
|
N/A | |
Recruiting |
NCT03698149 -
ECoG BMI for Motor and Speech Control
|
N/A | |
Not yet recruiting |
NCT05621213 -
Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation
|
N/A | |
Terminated |
NCT03373981 -
Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS
|
N/A | |
Completed |
NCT04165850 -
Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS
|
Phase 2 |